Jefferies analyst Roger Song sets a price target of $99 for NKTR, indicating a potential increase of 68.54%.NKTR's stock price surged over 15% following positive phase 2b study results of rezpegaldesleukin for atopic dermatitis.Rezpegaldesleukin demonstrated significant improvement in eczema area and severity index, with EASI-75 response deepening to 62% and vIGA-AD 0/1 response increasing to 38%.Nektar Therapeutics, traded on the NASDAQ under the symbol NKTR, is a biopharmaceutical company focused on devel ...